Milprosa is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 21, 2030. Details of Milprosa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8580293 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(4 years from now) | Active |
| US10537584 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(3 years from now) | Active |
| US10548904 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Milprosa's patents.
Latest Legal Activities on Milprosa's Patents
Given below is the list of recent legal activities going on the following patents of Milprosa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jul, 2023 | US10548904 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jul, 2023 | US10537584 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 May, 2021 | US8580293 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Feb, 2020 | US10548904 |
| Recordation of Patent Grant Mailed Critical | 04 Feb, 2020 | US10548904 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Jan, 2020 | US10537584 |
| Recordation of Patent Grant Mailed Critical | 21 Jan, 2020 | US10537584 |
| Email Notification Critical | 16 Jan, 2020 | US10548904 |
| Issue Notification Mailed Critical | 15 Jan, 2020 | US10548904 |
| Email Notification Critical | 10 Jan, 2020 | US10548904 |
FDA has granted several exclusivities to Milprosa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Milprosa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Milprosa.
Exclusivity Information
Milprosa holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Milprosa's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2023 |
US patents provide insights into the exclusivity only within the United States, but Milprosa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Milprosa's family patents as well as insights into ongoing legal events on those patents.
Milprosa's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Milprosa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 21, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Milprosa Generic API suppliers:
Progesterone is the generic name for the brand Milprosa. 11 different companies have already filed for the generic of Milprosa, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Milprosa's generic
Alternative Brands for Milprosa
Milprosa which is used for supporting embryo implantation and early pregnancy in infertile women undergoing ART treatment., has several other brand drugs using the same active ingredient (Progesterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Covis |
| ||
| Ferring |
| ||
| Mayne Pharma |
| ||
| Pfizer |
| ||
| Wyeth Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Progesterone, Milprosa's active ingredient. Check the complete list of approved generic manufacturers for Milprosa
About Milprosa
Milprosa is a drug owned by Ferring Pharmaceuticals Inc. It is used for supporting embryo implantation and early pregnancy in infertile women undergoing ART treatment. Milprosa uses Progesterone as an active ingredient. Milprosa was launched by Ferring Pharms Inc in 2020.
Approval Date:
Milprosa was approved by FDA for market use on 29 April, 2020.
Active Ingredient:
Milprosa uses Progesterone as the active ingredient. Check out other Drugs and Companies using Progesterone ingredient
Treatment:
Milprosa is used for supporting embryo implantation and early pregnancy in infertile women undergoing ART treatment.
Dosage:
Milprosa is available in system form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.78GM | SYSTEM | Discontinued | VAGINAL |